Compare abrdn Income Credit Strategies Fund (ACP) vs Illumina, Inc. (ILMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Illumina, Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Illumina, Inc. trades at $187.28 (market cap $29.01B). The key difference: Illumina, Inc. is far larger — about 44.2× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ACP | ILMN | |
|---|---|---|
Market Cap | $656.21M | $29.01B |
Sector | Financials | Health |
52-Week High | $5.98 | $194.33 |
52-Week Low | $5.01 | $91.00 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $30.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
ILMN trades at $191.76, up 1.63% with bullish technical momentum and strong earnings beats. The stock shows robust profitability with 66.2% gross margins and 19.42% net income margins, though valuations remain elevated with a P/E of 34.31. Recent product launches like StrataMap Spatial and NovaSeq X demand drive growth, while Roche's new Axelios sequencer introduces competitive pressure. Cash flow improved to $291M in 2025 after prior volatility.
Outlook remains positive with analyst consensus at Buy (51%) and a $168.89 price target, though current price exceeds consensus. Key risks include rising debt-to-asset ratios (29.93% in 2025) and China market challenges. Upside depends on execution against new competition and sustaining high-margin sequencing growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
